Atrial fibrillation (AF) is a prevalent cardiac arrhythmia that significantly elevates the risk of thromboembolic events, most notably ischaemic stroke. Anticoagulation therapy has long been a ...
Atrial fibrillation (AF) greatly increases the risk ofstroke. Long-term oral therapy with warfarin reducesthe risk of AF-related stroke by 62%, and nationalguidelines now call for warfarin therapy in ...
At what platelet count can I safely initiate long-term anticoagulation with warfarin (Coumadin) in cancer patients with thrombocytopenia and persistent atrial fibrillation (AF)?—EDGAR C. SALIRE, NP-C, ...
Twelve months of edoxaban is superior to three months for the reduction of thrombotic events in patients with cancer and distal deep vein thrombosis (DVT), according to late breaking research ...
In this session, data were presented from 3 separate trials that focused on potential ways to reduce the risk for bleeding in patients who require anticoagulation therapy, including the use of genetic ...
Karen L. Hassenplug, Pharm.D.; Jill S. Burkiewicz, Pharm.D., BCPS; Terri L. Jackson, Ph.D., B.S.Pharm.; Laura R. Peppers, Pharm.D., BCPS Identifying baseline ...
Recognized as innovative biopharma developing a potentially safer and superior anticoagulant for patients with implanted cardiac devices and rare cardiovascular conditions PONTE VEDRA, Fla., Nov. 19, ...
The 500 million international units (IUs) will include product specifically manufactured for donation allowing for a longer shelf life and enabling more people around the world to access life-saving ...
A novel gene therapy for hemophilia A led to sustained expression of the clotting factor those patients lack, resulting in a reduction – or in some cases complete elimination – of painful and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results